Simvastatin increases plasma NO2- and NO3- levels in patients with hypercholesterolemia

Atherosclerosis

Volumn 127, Issue 1, 1996, Pages 43-47

  Nakashima, Yasuhide ^a   Toyokawa, Tsuyoshi ^a   Tanaka, Seiya ^a   Yamashita, Kazuhito ^a   Yashiro, Akira ^a   Tasaki, Hiromi ^a   Kuroiwa, Akio ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

cholesterol lowering agent; hypercholesterolemia; plasma nitrite and nitrate

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRATE; NITRITE; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VASODILATATION;

ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; NITRATES; NITRITES; SIMVASTATIN; ULTRACENTRIFUGATION;

EID: 0030588598     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05933-3     Document Type: Article

References (25)

1. [1] Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 1987;327:524.
2. [2] Myers PR, Guerra R, Harrison DG. The vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocyteine than nitric oxide. Nature (London) 1990;345:16.
3. [3] Moncada S, Palmer RMJ, Higgs EA. The biological significance of nitric oxide formation from L-arginine. Biochem Soc Trans 1989;17:642.
4. [4] Moncada S. The L-arginine: nitric oxide pathway. Acta Physiol Scand 1992;145:201.
5. [5] Green LC, Wagner JG, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and (15N)-nitrate in biological fluid. Anal Biochem 1982;126:131.
6. [6] Kanno K, Hirata Y, Emori T et al. L-Arginine infusion induces hypotension and diuresis/natriuresis with concomitant increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin Exp Pharmacol Physiol 1992;19:619.
7. [7] Tanaka S, Yashiro A, Nanri H, Ikeda M, Nakashima Y, Kuroiwa A. Plasma nitric oxide level is inversely correlated with plasma cholesterol level. Circulation 1994;90:I-2571.
8. [8] Zeiher AM, Drexler H, Saurbier B, Just H. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension: endothelium-mediated coronary blood flow modulation in humans. J Clin Invest 1992;92:652.
9. [9] Egashira K, Inou T, Yamada A, Hirooka Y, Maruoka Y, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91:29.
10. [10] Creager MA, Cooke JP, Mendelson ME et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228.
11. [11] Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391.
12. [12] Chowienczyk PJ, Watts GF, Cockcrof TJR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992;340:1430.
13. [13] Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496.
14. [14] Egashira K, Hirooka Y, Kai H et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hyperlipidemia. Circulation 1994;89:2519.
15. [15] Allain CC, Poon LC, Chan CSG. Enzymatic determination of total serum cholesterol. Clin Chem 1794;20:470.
16. [16] Yashiro A, Nakashima Y, Segawa J, Kawashima T, Kuroiwa A. Factors predictive of marked decrease in HDL-C by probucol treatment. Artery 1990;18:16.
17. [17] MAAS investigators, Effect of simvastatin on coronary atheroma; the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633.
18. [18] The Scandinavian Simvastatin Survial Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383.
19. [19] Green LC, de Luzuriaca KR, Wagner DA. Nitrate biosynthesis in man. Proc Natl Acad Sci USA 1981;78:7764.
20. [20] Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990;81:1586.
21. [21] Jakody L, Senaratne MP, Thompson AB, Kappagoda CT. Endothelium-dependent relaxation in experimental atherosclerosis in the rabbit. Circ Res 1987;60:251.
22. [22] Shimokawa H, Vanhoutte PM. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res 1989;64:900.
23. [23] Galle J, Nuisch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoprotein on formation and inactivation of EDRF. Arterioscler Thromb 1991;11:198.
24. [24] Minor LM Jr, Myers PR, Guerra R Jr, Bates JM, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990;86:2109.
25. [25] Kuhn FE, Nohler ER, Satler LF, Reagan K, Lu DY, Rackley CE, Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 1991;68:1425.